Global impression ‐ no improvement ‐ medium term As defined in each study · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ medium/long term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short/medium term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: no improvement ‐ medium termAs defined in each study · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hospital admissions · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Leaving the study early ‐ short/medium term Rate of attrition · patients with schizophrenia or related psychoses
It is very uncertain whether FLUPENTHIXOL DECANOATE changes leaving the study early ‐ short term Rate of attrition compared with ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse effects: general ‐ movement disorders ‐ requiring anticholinergic medication ‐ short term Numbers requiring anticholinergic medication · patients with schizophrenia or related psychoses
It is very uncertain whether FLUPENTHIXOL DECANOATE changes adverse effects: general ‐ movement disorders ‐ requiring… compared with ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Economic outcomes ‐ long term ‐ not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: mental state ‐ relapse ‐ medium term Relapse rate · patients with schizophrenia or related psychoses
FLUPENTHIXOL DECANOATE showed no clear difference in clinical response: mental state ‐ relapse ‐ medium term Relapse rate compared with OTHER DEPOT ANTIPSYCHOTICS (low certainty).
1 finding from 1 review
Clinical response: mental state ‐ general score ‐ skew Brief Psychiatric Rating Scale (BPRS) · patients with schizophrenia or related psychoses
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether perazine changes acceptability of treatment Leaving the study early due to any reason compared with placebo (very low certainty).
1 finding from 1 review
Movement disorders number of participants receiving antiparkinson medication · patients with schizophrenia
It is very uncertain whether perazine changes movement disorders number of participants receiving antiparkinson… compared with other antipsychotics (very low certainty).
1 finding from 1 review
Adverse effects – leaving the study early due to adverse effects – overall tolerability – total · patients with schizophrenia
Perazine showed no clear difference in overall tolerability Leaving the study early due to adverse events compared with other antipsychotics (low certainty).
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · patients with schizophrenia
Perazine showed no clear difference in acceptability of treatment Leaving the studies early due to any reason compared with other antipsychotics (low certainty).
1 finding from 1 review
Satisfaction with care ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Global state change over time (no better or deterioration) · patients with schizophrenia
Perazine may leads to lower global state change over time (no better or deterioration) compared with placebo (low certainty).
1 finding from 1 review
Mental state: 2. Not improved (BPRS, < 30% decrease in BPRS score) · patients with schizophrenia
Perazine showed no clear difference in overall mental state less than 30% BPRS reduction compared with placebo (low certainty).
1 finding from 1 review